B. Mitton, N. Federman. Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/428789. PMID: 22566752.
E. Pennacchioli, M. Fiore, P. Collini, S. Radaelli i inni. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution.. „Ann Surg Oncol”. 17 (12), s. 3229-3333, 2010. DOI: 10.1245/s10434-010-1186-x. PMID: 20593242.
A. L. Folpe, A. T. Deyrup. Alveolar soft-part sarcoma: a review and update. „J Clin Pathol”. 59 (11), s. 1127-1132, 2006. DOI: 10.1136/jcp.2005.031120. PMID: 17071801.
H. Y. Huang, M. Y. Lui, M. Ladanyi. Nonrandom cell-cycle timing of a somatic chromosomal translocation: The t(X;17) of alveolar soft-part sarcoma occurs in G2. „Genes Chromosomes Cancer”. 44 (2), s. 170-176, 2005. DOI: 10.1002/gcc.20229. PMID: 15952162.
M. Ladanyi, M. Y. Lui, C. R. Antonescu, A. Krause-Boehm i inni. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.. „Oncogene”. 20 (1), s. 48-57, 2001. DOI: 10.1038/sj.onc.1204074. PMID: 11244503.
P. Argani, C. R. Antonescu, P. B. Illei, M. Y. Lui i inni. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. „Am J Pathol”. 159 (1), s. 179-192, 2001. DOI: 10.1016/S0002-9440(10)61684-7. PMID: 11438465.
SM. Nijman, E. M. Hijmans, S. El Messaoudi, M. M. van Dongen i inni. A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. „J Biol Chem”. 281 (31), 2006. DOI: 10.1074/jbc.M602312200. PMID: 16737956.
M. Tsuda, I. J. Davis, P. Argani, N. Shukla i inni. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. „Cancer Res”. 67 (3), s. 919-929, 2007. DOI: 10.1158/0008-5472.CAN-06-2855. PMID: 17283122.
X. Li, Z. Ye. Magnetic resonance imaging features of alveolar soft part sarcoma: report of 14 cases. „World J Surg Oncol”. 12, s. 36, 2014. DOI: 10.1186/1477-7819-12-36. PMID: 24517100.
M. Zhong, P. De Angelo, L. Osborne, M. Keane-Tarchichi i inni. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. „Am J Surg Pathol”. 34 (6), s. 757-766, 2010. DOI: 10.1097/PAS.0b013e3181dd577e. PMID: 20421778.
K. Tsuji, Y. Ishikawa, T. Imamura. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. „Hum Pathol”. 43 (3), s. 356-363, 2012. DOI: 10.1016/j.humpath.2011.05.004. PMID: 21835426.
K. Ogura, Y. Beppu, H. Chuman, A. Yoshida i inni. Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/907179. PMID: 22666000.
H. Wang, A. Jacobson, D. C. Harmon, E. Choy i inni. Prognostic factors in alveolar soft part sarcoma: A SEER analysis. „J Surg Oncol”. 113 (5), s. 581-586, Apr 2016. DOI: 10.1002/jso.24183. PMID: 26804150.
A. Ogose, Y. Yazawa, T. Ueda, T. Hotta i inni. Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. „Oncology”. 65 (1), s. 7-13, 2003. DOI: 10.1159/000071199. PMID: 12837977.
D. Orbach, B. Brennan, M. Casanova, C. Bergeron i inni. Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups. „Pediatr Blood Cancer”. 60 (11), s. 1826-1832, 2013. DOI: 10.1002/pbc.24683. PMID: 23857870.
W. L. Read, F. Williams. Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases. „Case Rep Oncol”. 9 (3). s. 639-643. DOI: 10.1159/000450545. PMID: 27920695.
S. Stacchiotti, T. Negri, N. Zaffaroni, E. Palassini i inni. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. „Ann Oncol”. 22 (7), s. 1682-1690, 2011. DOI: 10.1093/annonc/mdq644. PMID: 21242589.
S. George, P. Merriam, R. G. Maki, AD. Van den Abbeele i inni. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. „J Clin Oncol”. 27 (19), s. 3154-3160, Jul 2009. DOI: 10.1200/JCO.2008.20.9890. PMID: 19451429.
S. Stacchiotti, E. Tamborini, A. Marrari, S. Brich i inni. Response to sunitinib malate in advanced alveolar soft part sarcoma. „Clin Cancer Res”. 15 (3), s. 1096-1104, 2009. DOI: 10.1158/1078-0432.CCR-08-2050. PMID: 19188185.
S. Radaelli, S. Stacchiotti, P. G. Casali, A. Gronchi. Emerging therapies for adult soft tissue sarcoma. „Expert Rev Anticancer Ther”. 14 (6), s. 689-704, Jun 2014. DOI: 10.1586/14737140.2014.885840. PMID: 24555529.
P. Heudel, P. Cassier, O. Derbel, A. Dufresne i inni. Pazopanib for the treatment of soft-tissue sarcoma. „Journal of Clinical Pharmacology”. 4, s. 65–70, 2012. DOI: 10.2147/CPAA.S33195. PMID: 23204874. PMCID: PMC3508654.
T. Nakamura, A. Matsumine, A. Kawai, N. Araki i inni. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. „Cancer”. 122 (9), s. 1408-1416, 2016. DOI: 10.1002/cncr.29961. PMID: 26970174.
S. Kummar, D. Allen, A. Monks, E. C. Polley i inni. Cediranib for metastatic alveolar soft part sarcoma. „J Clin Oncol”. 31 (18), s. 2296-2302, 2013. DOI: 10.1200/JCO.2012.47.4288. PMID: 23630200.
I. Judson, M. Scurr, K. Gardner, E. Barquin i inni. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. „Clin Cancer Res”. 20 (13), s. 3603-3612, 2014. DOI: 10.1158/1078-0432.CCR-13-1881. PMID: 24714778.
A. J. Wagner, J. M. Goldberg, S. G. Dubois, E. Choy i inni. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. „Cancer”. 118 (23), s. 5894-5902, 2012. DOI: 10.1002/cncr.27582. PMID: 22605650.
M. L. Kayton, P. Meyers, L. H. Wexler, W. L. Gerald i inni. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. „J Pediatr Surg”. 41 (1), s. 187-193, 2006. DOI: 10.1016/j.jpedsurg.2005.10.023. PMID: 16410131.
B. Mitton, N. Federman. Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/428789. PMID: 22566752.
P. H. Lieberman, M. F. Brennan, M. Kimmel, R. A. Erlandson i inni. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. „Cancer”. 63 (1), s. 1-13, 1989. PMID: 2642727.
E. Pennacchioli, M. Fiore, P. Collini, S. Radaelli i inni. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution.. „Ann Surg Oncol”. 17 (12), s. 3229-3333, 2010. DOI: 10.1245/s10434-010-1186-x. PMID: 20593242.
A. L. Folpe, A. T. Deyrup. Alveolar soft-part sarcoma: a review and update. „J Clin Pathol”. 59 (11), s. 1127-1132, 2006. DOI: 10.1136/jcp.2005.031120. PMID: 17071801.
H. Y. Huang, M. Y. Lui, M. Ladanyi. Nonrandom cell-cycle timing of a somatic chromosomal translocation: The t(X;17) of alveolar soft-part sarcoma occurs in G2. „Genes Chromosomes Cancer”. 44 (2), s. 170-176, 2005. DOI: 10.1002/gcc.20229. PMID: 15952162.
M. Ladanyi, M. Y. Lui, C. R. Antonescu, A. Krause-Boehm i inni. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.. „Oncogene”. 20 (1), s. 48-57, 2001. DOI: 10.1038/sj.onc.1204074. PMID: 11244503.
P. Argani, C. R. Antonescu, P. B. Illei, M. Y. Lui i inni. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. „Am J Pathol”. 159 (1), s. 179-192, 2001. DOI: 10.1016/S0002-9440(10)61684-7. PMID: 11438465.
SM. Nijman, E. M. Hijmans, S. El Messaoudi, M. M. van Dongen i inni. A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. „J Biol Chem”. 281 (31), 2006. DOI: 10.1074/jbc.M602312200. PMID: 16737956.
M. Tsuda, I. J. Davis, P. Argani, N. Shukla i inni. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. „Cancer Res”. 67 (3), s. 919-929, 2007. DOI: 10.1158/0008-5472.CAN-06-2855. PMID: 17283122.
X. Li, Z. Ye. Magnetic resonance imaging features of alveolar soft part sarcoma: report of 14 cases. „World J Surg Oncol”. 12, s. 36, 2014. DOI: 10.1186/1477-7819-12-36. PMID: 24517100.
J. Rosai, P. Dias, D. M. Parham, D. N. Shapiro i inni. MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. „Am J Surg Pathol”. 15 (10), s. 974-981, 1991. PMID: 1656801.
G. Tallini, D. M. Parham, P. Dias, C. Cordon-Cardo i inni. Myogenic regulatory protein expression in adult soft tissue sarcomas. A sensitive and specific marker of skeletal muscle differentiation. „Am J Pathol”. 144 (4), s. 693-701, 1994. PMID: 8160771.
N. P. Wang, C. E. Bacchi, J. J. Jiang, M. A. McNutt i inni. Does alveolar soft-part sarcoma exhibit skeletal muscle differentiation? An immunocytochemical and biochemical study of myogenic regulatory protein expression. „Mod Pathol”. 9 (5), s. 496-506, 1996. PMID: 8733764.
M. H. Cessna, H. Zhou, S. L. Perkins, S. R. Tripp i inni. Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. „Am J Surg Pathol”. 25 (9), s. 1150-1157, 2001. PMID: 11688574.
M. Zhong, P. De Angelo, L. Osborne, M. Keane-Tarchichi i inni. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. „Am J Surg Pathol”. 34 (6), s. 757-766, 2010. DOI: 10.1097/PAS.0b013e3181dd577e. PMID: 20421778.
K. Tsuji, Y. Ishikawa, T. Imamura. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript. „Hum Pathol”. 43 (3), s. 356-363, 2012. DOI: 10.1016/j.humpath.2011.05.004. PMID: 21835426.
K. Ogura, Y. Beppu, H. Chuman, A. Yoshida i inni. Alveolar soft part sarcoma: a single-center 26-patient case series and review of the literature. „Sarcoma”. 2012, 2012. DOI: 10.1155/2012/907179. PMID: 22666000.
N. Sherman, M. Vavilala, R. Pollock, M. Romsdahl i inni. Radiation therapy for alveolar soft-part sarcoma. „Med Pediatr Oncol”. 22 (6), s. 380-383, 1994. PMID: 7512190.
M. E. Anderson, F. J. Hornicek, M. C. Gebhardt, K. A. Raskin i inni. Alveolar soft part sarcoma: a rare and enigmatic entity. „Clin Orthop Relat Res”. 438, s. 144-148, 2005. PMID: 16131883.
H. Wang, A. Jacobson, D. C. Harmon, E. Choy i inni. Prognostic factors in alveolar soft part sarcoma: A SEER analysis. „J Surg Oncol”. 113 (5), s. 581-586, Apr 2016. DOI: 10.1002/jso.24183. PMID: 26804150.
P. Reichardt, T. Lindner, D. Pink, P. C. Thuss-Patience i inni. Chemotherapy in alveolar soft part sarcomas. What do we know?. „Eur J Cancer”. 39 (11), s. 1511-1516, 2003. PMID: 12855256.
A. Ogose, Y. Yazawa, T. Ueda, T. Hotta i inni. Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. „Oncology”. 65 (1), s. 7-13, 2003. DOI: 10.1159/000071199. PMID: 12837977.
D. Orbach, B. Brennan, M. Casanova, C. Bergeron i inni. Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups. „Pediatr Blood Cancer”. 60 (11), s. 1826-1832, 2013. DOI: 10.1002/pbc.24683. PMID: 23857870.
W. L. Read, F. Williams. Metastatic Alveolar Soft Part Sarcoma Responsive to Pazopanib after Progression through Sunitinib and Bevacizumab: Two Cases. „Case Rep Oncol”. 9 (3). s. 639-643. DOI: 10.1159/000450545. PMID: 27920695.
S. Stacchiotti, T. Negri, N. Zaffaroni, E. Palassini i inni. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. „Ann Oncol”. 22 (7), s. 1682-1690, 2011. DOI: 10.1093/annonc/mdq644. PMID: 21242589.
S. George, P. Merriam, R. G. Maki, AD. Van den Abbeele i inni. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. „J Clin Oncol”. 27 (19), s. 3154-3160, Jul 2009. DOI: 10.1200/JCO.2008.20.9890. PMID: 19451429.
S. Stacchiotti, E. Tamborini, A. Marrari, S. Brich i inni. Response to sunitinib malate in advanced alveolar soft part sarcoma. „Clin Cancer Res”. 15 (3), s. 1096-1104, 2009. DOI: 10.1158/1078-0432.CCR-08-2050. PMID: 19188185.
S. Radaelli, S. Stacchiotti, P. G. Casali, A. Gronchi. Emerging therapies for adult soft tissue sarcoma. „Expert Rev Anticancer Ther”. 14 (6), s. 689-704, Jun 2014. DOI: 10.1586/14737140.2014.885840. PMID: 24555529.
P. Heudel, P. Cassier, O. Derbel, A. Dufresne i inni. Pazopanib for the treatment of soft-tissue sarcoma. „Journal of Clinical Pharmacology”. 4, s. 65–70, 2012. DOI: 10.2147/CPAA.S33195. PMID: 23204874. PMCID: PMC3508654.
T. Nakamura, A. Matsumine, A. Kawai, N. Araki i inni. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study. „Cancer”. 122 (9), s. 1408-1416, 2016. DOI: 10.1002/cncr.29961. PMID: 26970174.
S. Kummar, D. Allen, A. Monks, E. C. Polley i inni. Cediranib for metastatic alveolar soft part sarcoma. „J Clin Oncol”. 31 (18), s. 2296-2302, 2013. DOI: 10.1200/JCO.2012.47.4288. PMID: 23630200.
I. Judson, M. Scurr, K. Gardner, E. Barquin i inni. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. „Clin Cancer Res”. 20 (13), s. 3603-3612, 2014. DOI: 10.1158/1078-0432.CCR-13-1881. PMID: 24714778.
A. J. Wagner, J. M. Goldberg, S. G. Dubois, E. Choy i inni. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. „Cancer”. 118 (23), s. 5894-5902, 2012. DOI: 10.1002/cncr.27582. PMID: 22605650.
C. H. Wang, N. Lee, L. S. Lee. Successful treatment for solitary brain metastasis from alveolar soft part sarcoma. „J Neurooncol”. 25 (2), s. 161-166, 1995. PMID: 8543972.
M. L. Kayton, P. Meyers, L. H. Wexler, W. L. Gerald i inni. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. „J Pediatr Surg”. 41 (1), s. 187-193, 2006. DOI: 10.1016/j.jpedsurg.2005.10.023. PMID: 16410131.